The Filing Desk

Abeona Therapeutics vs SAB Biotherapeutics

Abeona Therapeutics ABEO · SAB Biotherapeutics SABS · Biotechnology

Free cash flow was −$84 million at Abeona Therapeutics and −$46 million at SAB Biotherapeutics.

Side by side

Abeona TherapeuticsSAB Biotherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$0M
Revenue growth—−100.0%
Revenue growth a year, last 5 years−10.3%—
Gross margin73.7%—
Operating margin−1,536.9%—
Net margin1,223.1%—
Free cash flow−$84M−$46M
Free cash flow margin−1,448.5%—
Return on capital—−145.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count61.1%562.3%
Last close$2.45$2.91
P/E at the last close——
Insider trades, last 12 monthssold $3.5 million—
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Abeona TherapeuticsSAB Biotherapeutics
Operating margin
Percent of revenue
Abeona TherapeuticsSAB Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Abeona TherapeuticsSAB Biotherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Abeona Therapeutics and SAB Biotherapeutics pages.